# Treatment of Recurrent IgA Nephropathy After Kidney Transplantation: Case Report and Comprehensive Literature Review

## TL;DR

This paper reports a successful treatment of recurring IgA nephropathy in a kidney transplant patient using a new drug combination.

## Contribution

The study demonstrates the effectiveness of combining targeted-release budesonide with sparsentan in managing recurrent IgA nephropathy post-transplant.

## Key findings

- Targeted-release budesonide combined with sparsentan successfully managed recurrent IgA nephropathy in a kidney transplant patient.
- Early recognition and treatment are crucial for preserving long-term allograft function in such cases.

## Abstract

Recurrent IgA nephropathy after kidney transplantation remains a major cause of graft dysfunction. This case highlights successful management with targeted‐release budesonide combined with sparsentan, underscoring the importance of early recognition and the promise of emerging therapies to preserve long‐term allograft function.